A Pilot Phase 2a, Multicenter, Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules After Oral Administration in Pediatric Subjects (9 to 12 Years, Inclusive) With Attention-deficit Hyperactivity Disorder
Latest Information Update: 16 Jan 2023
At a glance
- Drugs Centanafadine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Pharmacokinetics
- Sponsors Otsuka Pharmaceutical Development & Commercialization
Most Recent Events
- 27 Feb 2020 Status changed from recruiting to completed.
- 05 Nov 2019 Status changed from not yet recruiting to recruiting.
- 11 Sep 2019 New trial record